TOFRANIL- imipramine hydrochloride tablet, sugar coated United States - English - NLM (National Library of Medicine)

tofranil- imipramine hydrochloride tablet, sugar coated

thompson medical solutions llc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression – for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis – may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval sho

APO-NICORANDIL nicorandil 10 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-nicorandil nicorandil 10 mg tablet blister pack

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 10 mg - tablet, uncoated - excipient ingredients: povidone; cetyl alcohol; croscarmellose sodium; sodium stearylfumarate; mannitol - nicorandil is indicated for the treatment of chronic stable angina pectoris.

APO-NICORANDIL nicorandil 20 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-nicorandil nicorandil 20 mg tablet blister pack

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; mannitol; povidone; cetyl alcohol; sodium stearylfumarate - nicorandil is indicated for the treatment of chronic stable angina pectoris.

IKOREL Nicorandil 20mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ikorel nicorandil 20mg tablet blister pack

sanofi-aventis australia pty ltd - nicorandil, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; mannitol; croscarmellose sodium - ikorel is indicated for the treatment of chronic stable angina pectoris.

IKOREL Nicorandil 10mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ikorel nicorandil 10mg tablet blister pack

sanofi-aventis australia pty ltd - nicorandil, quantity: 10 mg - tablet, uncoated - excipient ingredients: mannitol; maize starch; croscarmellose sodium; stearic acid - ikorel is indicated for the treatment of chronic stable angina pectoris.

ELDEPRYL selegiline hydrochloride 5 mg tablet Australia - English - Department of Health (Therapeutic Goods Administration)

eldepryl selegiline hydrochloride 5 mg tablet

orion pharma (aus) pty limited - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; maize starch; microcrystalline cellulose; mannitol - as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor) as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor)

Tofranil Australia - English - Department of Health (Therapeutic Goods Administration)

tofranil

link medical products pty ltd t/a link pharmaceuticals - imipramine hydrochloride -

TOFRANIL Tablets 10 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

tofranil tablets 10 milligram

novartis pharmaceuticals uk ltd - imipramine hydrochloride - tablets - 10 milligram